Alkem Laboratories Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Vikas Gupta
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.4yrs |
| CEO ownership | n/a |
| Management average tenure | 1.4yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Alkem Laboratories Limited's (NSE:ALKEM) Shares May Have Run Too Fast Too Soon
Feb 01
Is Alkem Laboratories (NSE:ALKEM) A Risky Investment?
Jan 10Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models
Nov 16Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching
Nov 15What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You
Sep 24Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 03Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 13Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 27Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00
Jul 13Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 27Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00
Jun 13Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Jun 01Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)
May 22Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 13CEO
Vikas Gupta
1.4yrs
Tenure
Dr. Vikas Gupta is Chief Executive Officer of Alkem Laboratories Limited from September 22, 2023. He has experience in Pharmaceutical Sector and brings with him deep experience across therapeutic areas inc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 51.5yrs | ₹200.60m | 13.31% ₹ 83.6b | |
| VP of Sales & Marketing and Executive Director | no data | ₹44.50m | 0% ₹ 0 | |
| MD & Executive Director | 1.4yrs | ₹81.50m | 0.0065% ₹ 41.0m | |
| Executive Director | no data | ₹104.30m | 8.58% ₹ 53.9b | |
| Executive Director | 2.4yrs | ₹96.60m | 0.086% ₹ 539.7m | |
| Executive Director | no data | ₹104.10m | 8.77% ₹ 55.1b | |
| Chief Executive Officer | 1.4yrs | no data | no data | |
| President & Chief Medical Officer | no data | no data | no data | |
| President & Head Medtech Business | 1.2yrs | no data | no data | |
| President & Global HR Head | no data | no data | no data | |
| CFO & President of Finance | 1yr | no data | no data | |
| Head of Operations | no data | no data | 0.060% ₹ 378.0m |
1.4yrs
Average Tenure
55yo
Average Age
Experienced Management: ALKEM's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 51.5yrs | ₹200.60m | 13.31% ₹ 83.6b | |
| VP of Sales & Marketing and Executive Director | 5.3yrs | ₹44.50m | 0% ₹ 0 | |
| MD & Executive Director | 11.5yrs | ₹81.50m | 0.0065% ₹ 41.0m | |
| Executive Director | 16.3yrs | ₹104.30m | 8.58% ₹ 53.9b | |
| Executive Director | 2.4yrs | ₹96.60m | 0.086% ₹ 539.7m | |
| Executive Director | 3.2yrs | ₹104.10m | 8.77% ₹ 55.1b | |
| Independent Director | 9.9yrs | ₹3.30m | no data | |
| Independent Director | 9.7yrs | ₹3.10m | no data | |
| Independent Director | 9.7yrs | ₹3.00m | no data | |
| Independent Director | 4.9yrs | ₹3.20m | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 2.5yrs | ₹2.70m | no data |
7.5yrs
Average Tenure
62yo
Average Age
Experienced Board: ALKEM's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 11:29 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alkem Laboratories Limited is covered by 36 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |
| Shrikant Akolkar | Angel Broking Private Limited |